Comparative Pharmacology
Head-to-head clinical analysis: FERAHEME versus MONOFERRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERAHEME versus MONOFERRIC.
FERAHEME vs MONOFERRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferumoxytol is a superparamagnetic iron oxide nanoparticle coated with a semisynthetic carbohydrate shell. It serves as a source of iron for hemoglobin synthesis and replenishes iron stores. The iron core is processed intracellularly to release iron, which is then incorporated into hemoglobin or stored as ferritin. The carbohydrate shell is metabolized and eliminated.
Monomeric ferric iron replaces iron stores and is incorporated into hemoglobin, myoglobin, and enzymes, supporting erythropoiesis and oxygen transport.
510 mg intravenously once, followed by a second 510 mg dose 3 to 8 days later, not exceeding 1020 mg per course.
100-200 mg elemental iron intravenously as a single dose, repeated weekly until iron stores are replete. Typical total dose is 1-2 g.
None Documented
None Documented
Terminal half-life of ferumoxytol (iron core) is approximately 14-21 hours; for the intact nanoparticle (carbohydrate shell), half-life is about 15 hours. Clinically, iron is continuously released and incorporated, extending effects beyond half-life.
Terminal half-life: 10-14 hours for ferric carboxymaltose core; clinical effect persists for weeks due to iron utilization
Renal: minimal (<1% as intact drug); primarily degraded endogenously with iron incorporated into hemoglobin; fecal/biliary elimination of unabsorbed iron is negligible.
Renal: <1% unchanged; Biliary/fecal: >99% as iron in RBC turnover and storage
Category C
Category C
Iron Supplement
Iron Supplement